EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 875as such, no dose adjustment of oral semaglutide is likely to be required when administered with omeprazole. Acknowledgments We thank all participants, investigators, and trial staff who were involved in the conduct of the trial. We thank Christin Løth Hertz (Novo Nordisk A/ S) for her review and input into the manuscript. Funding This trial was funded by Novo Nordisk A/S. Declaration of interest TA Bækdal is an employee of Novo Nordisk A/S and own stocks in the company; A Breitschaft is an employee of PAREXEL International GmbH; C W Hansen and A Navarria are employees of Novo Nordisk A/S. All trial subjects received remuneration from Novo Nordisk A/S for trial participa- tion and this was approved by the Ethics Committee. Writing assistance and editorial support, provided by Graham Allcock of Spirit Medical Communications Ltd., was utilized in the writing of this paper and funded by Novo Nordisk A/S. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials dis- cussed in the manuscript apart from those disclosed. 
